Scholar Rock Soars 23% on Positive FDA Meeting for SMA Treatment
Scholar Rock (SRRK) shares jump 23% after constructive FDA meeting regarding apitegromab treatment for spinal muscular atrophy, with 2026 approval anticipated.
/ 3 items
#SRRK↓
BofA Initiates Scholar Rock with Buy Rating: $53 Target on Promising SMA Therapy
Bank of America initiates coverage of Scholar Rock with Buy rating and $53 price target, citing apitegromab's breakthrough potential in spinal muscular atrophy treatment with $2B peak sales forecast.
Scholar Rock’s Apitegromab Application Declined by FDA Due to Manufacturer Issues
Scholar Rock’s potential new SMA treatment, Apitegromab, received a delay from the FDA due to manufacturing site issues, not the drug's safety or effectiveness.